Chinese biopharma firm IMPACT closes $55m Series D+ round to advance cancer drugs
The Series D+ round was led by GTJA Investment Group and Beijing-based state capital investor Kingray Capital.
Source: dealstreetasia.com
Stay updated with breaking news from Leiwen Chen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Series D+ round was led by GTJA Investment Group and Beijing-based state capital investor Kingray Capital.